Infracentimetric breast cancers represent 25-30% of newly diagnosed cancers in France. While tumors under 1 cm often have a good prognosis, up to 20% can be node positive. Early and accurate diagnosis is important but poses challenges, as these small lesions can be missed on screening or have misleading appearances. High quality imaging is needed while understanding limitations. Obtaining preoperative tissue samples is also key to assessing prognosis factors like grade and receptors. When in doubt, biopsy is preferable to close monitoring alone.
Introduction to mammography and its equipment.
Different views on mammography & supplementary views.
Birads mammographic lexicon
Birads ultrasound lexicon
Imaging of suspicious mammary lymph nodes
Categories in BIRADS 2013.
Sonographic evaluation of breast Dr. Muhammad Bin Zulfiqar
In this we will discuss role of high resolution Ultrasound in breast pathologies.
We will further discuss the role of Elastography in characterization of BIRADS.
Here are slides from my 10-minute talk on breast cancer screening for an AACR webinar (Feb 16, 2017). I'll share the webinar link when that becomes available.
Introduction to mammography and its equipment.
Different views on mammography & supplementary views.
Birads mammographic lexicon
Birads ultrasound lexicon
Imaging of suspicious mammary lymph nodes
Categories in BIRADS 2013.
Sonographic evaluation of breast Dr. Muhammad Bin Zulfiqar
In this we will discuss role of high resolution Ultrasound in breast pathologies.
We will further discuss the role of Elastography in characterization of BIRADS.
Here are slides from my 10-minute talk on breast cancer screening for an AACR webinar (Feb 16, 2017). I'll share the webinar link when that becomes available.
Wendy Noe, education coordinator for the Central Indiana Affiliate of Susan G. Komen for the Cure® presents an overview of breast cancer information, facts and advances in treatment.
Breast Cancer Management & Surgical ConsiderationsRiaz Rahman
Clinical overview and surgical considerations for management of Primary Breast Cancer and other subtypes. Covers screening recommendations, mammography (including BIRADS score interpretation), pathophysiology, staging, prognosis, surgical management, breast anatomy, non-surgical management, follow-up considerations. Given at Jackson Park Medical Center on 1/30/2014. Includes references.
Breast Carcinoma.
Breast cancer is a malignant (cancerous) tumor that starts in the cells of the breast and spread to other tissues.
The most common form of cancer among women
It is estimated that each year more than 83,000 cases of breast cancer are reported in Pakistan. Nearly 40,000 women die, just due to this deadly disease
Carcinoma of the breast occurs commonly in the western world,accounting for 3–5% of all deaths in women. In developing countries it accounts for 1–3% of death
The most common form of cancer among women
The second most common cause of cancer related mortality
1 of 8 women (12.2%)
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Jean Yves Seror : Breast cancer : Small lesion imaging features
1. « Israeli-French Breast Cancer Update »
Prevention, Detection and Treatment,
Multidisciplinary approach
Dr Jean-Yves SEROR (Paris, France)
Small lesions ≤ 1 cm.
Imaging features.
2. T1a > 1mm and < 5mm T1b > 5 mm and < 10mm
T1c > 10mm et < 20 mm
Global survival at 5 years vs size
S < 20 mm 91 %
20 < S < 50 mm 80 %
S > 50 mm 60 %
Definition TNM T1a and T1b (T1< 20 mm)
Cancello & al, Br Can res and TTT 2011
N+
N-
T < 10 mm
Recurrence at 10 years <10%
• Tumors most frequently not palpable, detected through screening
• Infra-centimetric = Not palpable
• HER2 +
• Triple Negative
• Young old patientGood prognosis
Biological
Heterogenicity
3. In France , the infra centimetric breast cancers
represent today 25 to 30 % of these newly diagnosed
cancers.
37 % of the invasive cancers diagnosed within this
screening campaign have a size ≤ 10mm
France : National Breast Cancer Screening
4. Tumor size : The largest diameter of the bigger tumoral
nodule present
Definitions
In case of difference between the macroscopic and microscopic measure, the
microscopic measure of the invasive contingent should be taken into account
for the grading
Lobular Invasive carcinoma: underestimation of the size
7 mm
• When measuring, do not take into account
the in situ adjacent carcinomas
• In case of multiple tumor, do not sum sizes
6. In case of multiple tumor
• Do not sum the sizes for the TNM
• Total size : surgical management
Infra centimetric tumors : MULTIFOCAL
7. Tumoral distribution
Regarding small size tumors (≤ 9 mm), vascular embolus and nodes extension
are most frequent for multifocal tumors 1
71. Tot T, Pekár G, Hofmeyer S, et al. The distribution of lesions in 1-14-mm invasive breast carcinomas and its relation to metastatic potential. Virchows Arch.
2009 Aug;455(2):109-15.
137 tumors between 1 & 9 mm (55 %)
Unifocal tumors Multifocal tumors
Invasive carcinoma 1-9 mm 97 71 % 40 29 %
Vascular embolus 9 9 % 14 35 %
RR = 3.8144
95 % CI = 1.7960-8.0870
Ganglionic extension 5 5 % 5 13 %
RR = 2.4250
95 % CI = 1.7424-7.9266
8. Infra centimetric tumors and mammography
Infra centimetric tumors and ultrasound
Infra centimetric tumors and MRI
Imaging specificities for lesions < 1 cm
9. 9
Infra centimetric tumors
and mammography
Compared to tumors > 2 cm, detection of infra centrimetric tumors not
seen on mammography but only under ultrasound 1: x 2,2
1. Bae MS, Han W, Koo HR et al. Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms.
Cancer Sci. 2011 Oct;102(10):1862-7.
Se 80% [78-82%]
Density 1 98%
Density 2 83%
Density 3 64%
Density 4 48%
2. DEMIST Digital Mammographic ImagingScreeningTrial ) Pisano ED et al. New Engl. J. Med 2005
The mammography sensitivity is related to the breast density
• The higher the breast density, the lower the detection sensitivity1
• Variation of 64 % for breasts with a very high density to 87 % for very fatty
breasts 2
7 mm
10. Infra centimetric tumors and mammography
16 %
43 %
21 %
43 %
Isolated microcalcifications cluster ( 43% ) Indicating an in situ lesion
Rounded ( 20 %) or spiculated opacity (21%)
Opacity and microcalcifications ( 16 % )
Inv Carcinoma
Radial scar
11. With mammography small cancers can be seen :
microcalcifications
Bi-Rads 3 BIRADS 4 ?
• Analysis and detection of microcalcifications clusters on X-ray images
Magnification views +++
• BIRADS : THE MORPHOLOGY is the first semiologic element to be taken into
account before the evolvement
Diagnostic pitfall
13 months
DCIS comédo
12. 1. Berg WA et al Cystic breast masses and the acrin 6666 experience. Radiol Clin North Am 2010;48:931-87
• These small rounded tumors should not be
wrongly interpreted as intra-mammary
lymph nodes.
• You should be careful with stable lesions
compared with the last medical balance and
with lesions not found again under
ultrasound.
• Women with Family history ++ Misleading
aspect of some lesions : rounded, regular,
pseudo cystic image.
With mammography small cancers can be seen (follow) :
Round tumor with benign appearance 1
Diagnostic pitfall
13. P David, J Le Sein Septembre 2004)
Relation between size and tumoral growth
Misleading rounded shapes
Irregular outlines
Bi-Rads 3 : if follow up ….
Opacity control at 4 months
Microcalcifications at 6 months
• Growth speed
• Intensity of the surrounding tissue reaction
14. 2009
2009
Bi-Rads 2 ? Bi-Rads 3 ?
Eric L Rosen and al Malignant Lesions Initially Subjected to Short-term Mammographic Follow-up Radiology 2002;223:221-228
2011 2011
Rosen: 4/12 opacities classified as node
15. 3. Burrell HC, Sibbering DM, Wilson AR et al. Screening interval breastcancer : mammographic features and pronostic factors. Radiology
1996;199:811-7.
4. Andersson I, Ikeda DM, Zackrisson S et al. Breast tomosynthesis and digital mammography: a comparison of breast cancer visibility and
BIRADS classification in a population of cancers with subtle mammographic findings. Eur Radiol. 2008 Dec;18(12):2817-25.
15
• Variation of the aspect according to the
incidence or visibility under a sole incidence
• The most frequent cause of interval cancers 3
• The breast tomosynthesis by reducing the
tumor and gland superposition effects ,
should improve the sensibility versus the
mammography 4
With mammography small cancers can be seen as :
architectural distortion
Diagnostic pitfall
19. 4 radiologists
12631 women
Cancer n = 121
Mammo 2D Mammo 2D
+
Mammo 3D
2 incidences
Delta p
False positives 6,1% 5,3% 15% P < 0,001
Cancers detection
121 soit 9,5 %o
77/121
6,1%o
101/121
8%o
24
27%
P < 0,001
Invasive cancers detection
56
4,4%o
81
6,4%o
25
40%
P < 0,001
Oslo trial Nov 2010 – Dec 2011 25 000 women
Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-
based screening program.
Skaane P et Al. Radiology. 2013 Apr;267(1):47-56.
20. BIRADS 0 ?
Doubt in mammography with an abnormality not accessible for a
biopsy under ultrasound or stereotaxy
22. In front of a small tumor detected under ultrasound, the signs with
the highest cancer positive predictive value are :
The irregular shape : 62 %
The orientation not parallel to the skin : 69 %
The spiculated margins : 86 %
1 sign only : eliminate the benignancy
Ultrasound signs : T1b > T1a
Infra centimetric tumors and ultrasound
The diagnostic value of the ultrasound is superior if the echography is guided by an
abnormality detected on the mammography vs screening ultrasound
23. 1. Iso-echogenic lesions (10 % of cancers)
2. Some high grade small cancers
Posterior reinforcement of the ultrasonic beam due to their high
cellularity
Regular margins due to their fast growth
Histology : Papillary carcinoma
Infra-centimetric tumors and ultrasound
Diagnostic Pitfall
24. 1 2 3
Cysts , fibroadenoma and carcinoma ?
Medularry Carcinoma
Size 10 mm RH- Her2 +
Post puncture
25. Masses Enhancement
(visible tumor in 3 planes > 5mm)
Non mass Enhancement Foci each enchancement < 5mm
Enhancing lesions
Sensibility1,2
95-100 % in infiltrative Carcinoma
70-75 % in Ductal carcinoma In situ (DCIS)
1 Liberman L, Morris EA, Joo-Young Lee M et al. AJR Breast lesions detected on MR Imaging: features and positive predictive value. AJR 2002;179:171-178
2 Schelfout K, Van Goethem M, Kersschot E, et al. Preoperative breast MRI in patients with invasive lobular breast cancer. Eur. Radiol 2004;14:1209–1216.
3 Fabre Demard N, Boulet P, Prat X et al. Breast MRI in invasive lobular carcinoma: diagnosis and staging].J Radiol 2005;86(Pt 1):1027–1034.
Infra centimetric tumors and RMI
73% Invasive carcinoma
• DCIS
• Invasive lobular carcinoma 3
Focal adenosis,Invasive carcinoma,
DCIS, papilloma, fibroadenoma, LN…
26. False negatives: the causes
Weak tumoral angiogenesis and therefore low enhancement :
• Histological type (5 % of the RMI FN)
Ductal Carcinoma In situ (DCIS)
Medularry Carcinoma Breast
Some Invasive Lobular Carcinoma (ILC) or with a consequent fibrous contingent
• Small size cancers (Up to 3 % of false negative)
Infra centimetric tumors and RMI
Diagnostic Pitfall
Enhancement
Absent (few or no angiogenesis)
Not seen (masked effect)
Wrong interpretation (Focus)
Be careful with the mammary gland PHYSIOLOGICAL ENHANCEMENT particularly during the 2nd part
of the menstruation ( RMI exam to be performed between the 7th and 13rd day of the menstruation)
28. 28
• FOCI 1,2
CARACTERIZATION
Punctiform enhancements < 5 mm
Not visible before injection +++ (T1 / T2)
Unique or multiple
• Up to 29 % of the patients presenting a suspicious lesion under mammography
or ultrasound
1. Kuhl CK, Kreft BP, Hauswirth A et al. [MR mammography at 0.5 tesla. II. The capacity to differentiate malignant and benign lesions in MR mammography at
0.5 and 1.5 T].] Rofo 1995 Jun;162(6):482-91.
2. Brown J, Smith RC, Lee CH. Incidental enhancing lesions found on MR imaging of the breast. AJR Am J Roentgenol. 2001 May;176(5):1249-54.
Infra centimetric breast carcinoma and RMI
Mass enhancement :
Invasive ductal Carcinoma
Foci : Non mass enhancement < 5mm
29. CCI SBR2 Re+ Rp- Her2 -
Right Breast ultrasound
45% echo-guided biopsy
55 % of the lesions not found
DeMartini et al. Utility of Targeted Sonography for Breast Lesions That Were Suspicious
on MRI. AJR 2009;192:1128
SECOND LOOK ULTRASOUND
30. VPP 96 % T > 20 MM
VPP 62% T < 20 MM
Microcalcifications
NME > 5 mm
32. Limits and difficulties of infra-centimetric lesions echo-
guided microbiopsies ( T1a < 5 mm)
Small size lesions?
3 -4 mm ? Visibility
Post biopsy for small size
lesions
Pre-operatory localization
X-ray ultrasound correlation
X-ray of the operative element
After biopsy of small lesions
(< 5mm)
33. “The mean size of such image-detected carcinomas
is 11mm and 90% will be node negative.”
“Errors in determining tumor size result from
summing the sizes of the carcinoma
• In multiple separate morcellated fragments
of a resection
• Or in the multiple separate fragments of a
core biopsy procedure.”
Issues with Tumor Size Assessment
Michael Lagios, MD Seminars Breast Disease 2006, Volume 3, No. 9
T1a et T1b
20 mm
10mm
34. Conclusion
Small lesions ≤ 1 cm. Imaging Features.
• Tumors with a good prognosis but up to 20% are N+
• Clinical exam + imaging : early diagnosis
• Delayed diagnosis : Pitfall
Histological
Screening
Misleading appearance
• Importance of a high quality imaging, knowing the limits.
• Pre-operative diagnosis +++
• In case of doubt, sampling rather than close control
35. Dr Jean-Yves SEROR (Paris, France)
« Israeli-French Breast Cancer Update »
Prevention, Detection and Treatment,
Multidisciplinary approach
Small lesions ≤ 1 cm.
Imaging features.